Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EntREG-SILICOFCM sacubitril/valsartan trial in hypertrophic cardiomyopathy
2018-004882-15Phase 2Completed
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sacubitril + valsartan in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by Universitätsklinikum Regensburg. Primary endpoint: Change in exercise tolerance. Started Mar 2019; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2018-004882-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004882-15.